Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pyrotinib and Capecitabine in HER2+ Micro-Invasive Breast Cancer
NCT05861271Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Fudan University. Started Jun 2023; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05861271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861271.